Kolexia
Durando Xavier Oncologie médicale
Durando Xavier
Oncologie médicale
Centre Jean-Perrin
Clermont-Ferrand, France
190 Activités
916 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs du cerveau Métastase tumorale Glioblastome Mélanome Tumeurs du sein triple-négatives Tumeurs du poumon Gliome Carcinomes

Collaborateurs

Voir plus
Mouret-Reynier Marie-Ange
Mouret-Reynier Marie-Ange
Centre Jean-Perrin, Clermont-Ferrand, France
Penault-Llorca Frederique
Penault-Llorca Frederique
Centre Jean-Perrin, Clermont-Ferrand, France
Chollet Philippe
Chollet Philippe
Centre Jean-Perrin, Clermont-Ferrand, France
Biau Julian
Biau Julian
Centre Jean-Perrin, Clermont-Ferrand, France

Industries

Voir plus
A+A
118 collaboration(s)
Dernière en 2023
B3TSI
28 collaboration(s)
Dernière en 2023
Pfizer
5 collaboration(s)
Dernière en 2023
Lilly
4 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
Breast cancer research and treatment   07 mars 2024
NANO-GBM: Phase I/II Study of AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma
Essai Clinique (Centre Jean-Perrin)   06 mars 2024
BIOMEDE 2: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
Essai Clinique (Chimerix)   29 février 2024
PROGLIO: Pilot Study of hPG80 (Circulating Progastrin) as a Blood Biomarker for High-grade Glial Tumors
Essai Clinique (Centre Jean-Perrin)   27 février 2024
REPARP: Prospective and Multicentric Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
Essai Clinique (Artios Pharma Ltd)   26 février 2024
INSTIGO Trial: Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients
Essai Clinique (Centre Jean-Perrin)   13 février 2024
StrateGlio: Phase III Randomised Trial Evaluating Treatment Intensification With Temozolomide in Adults With a Glioblastoma
Essai Clinique (Centre Oscar-Lambret)   08 février 2024
Consore: A Powerful Federated Data Mining Tool Driving a French Research Network to Accelerate Cancer Research.
International journal of environmental research and public health   07 février 2024
XenoBreast: A Prospective Study of Xenografts Development From Samples Taken From Surgical Specimens of Patients With Triple Negative or Luminal B Breast Cancer
Essai Clinique (Centre Jean-Perrin)   07 février 2024
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE): A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Essai Clinique (PMV Pharmaceuticals, Inc)   07 février 2024